Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1Phase 2 1

Status

Terminated 1Completed 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 4Genitourinary 2CNS 2Sarcoma 1Other hematologic neoplasm 1Head & Neck 1Dermatologic 1Breast 1

Conditions

Glioblastoma 2Glioma 1

Interventions

Temozolomide 171Bevacizumab 106Radiotherapy 87Radiation 38Cyclophosphamide 38Etoposide 34Carboplatin 34Magnetic Resonance Spectroscopy 32Irinotecan 32Radiosurgery 27Vincristine 25pembrolizumab 24Everolimus 23Cisplatin 23Nivolumab 22Radiotherapy, Intensity-Modulated 19Isotretinoin 19Filgrastim 19Erlotinib Hydrochloride 19Topotecan 18Lomustine 17Vorinostat 16Doxorubicin 16Granulocyte Colony-Stimulating Factor 15sargramostim 14antineoplaston A10 13Radiotherapy, Conformal 13antineoplaston AS 2-1 12Granulocyte-Macrophage Colony-Stimulating Factor 12dinutuximab 11

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Has results × infigratinib × CNS × Clear all
NCT04424966 2025-10-24

Infigratinib in Recurrent High-Grade Glioma Patients

St. Joseph's Hospital and Medical Center, Phoenix

Phase EARLY_PHASE1 Terminated
7 enrolled 18 charts
CNS

Glioblastoma, Glioma

NCT01975701 2019-12-04

A Phase 2 Study of BGJ398 in Patients With Recurrent GBM

Novartis

Phase 2 Completed
26 enrolled 10 charts
CNS

Glioblastoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡